Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for…
Medical - Diagnostics & Research
US, Redwood City [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -9.08 | 5.95 | 6.54 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -181.24 | -2.45 | -0.87 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -58.10 | 0.56 | 1.34 | |
| Cash | -5.91 | 9.28 | 9.86 | |
| Capex | -65.60 | -0.06 | -0.03 | |
| Free Cash Flow | 56.24 | -0.31 | -0.70 | |
| Revenue | 5.81 | 1.38 | 1.31 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -59.79 | 0.61 | 1.52 | |
| Operating Margin | 53.56 | -0.59 | -1.27 | |
| ROA | 35.57 | -0.07 | -0.10 | |
| ROE | -42.86 | -1.68 | -1.18 | |
| ROIC | 45.52 | -0.08 | -0.15 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of GH is permitted for members.
5
Growth
The "Growth Entry" for the Focus of GH is permitted for members.
6
Leverage & Liquidity